Linezolid Alone or Combined With Carbapenem Against Methicillin-resistant Staphylococcus Aureus (MRSA) in Ventilator-associated Pneumonia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01356472|
Recruitment Status : Unknown
Verified April 2011 by Ruijin Hospital.
Recruitment status was: Not yet recruiting
First Posted : May 19, 2011
Last Update Posted : May 19, 2011
|Condition or disease||Intervention/treatment||Phase|
|Methicillin-resistant Staphylococcus Aureus Pneumonia, Ventilator-Associated||Drug: Imipenem/cilastatin||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Linezolid Alone or Combined With Carbapenem Against Methicillin-resistant Staphylococcus Aureus (MRSA) in Vitro and in Ventilator-associated Pneumonia|
|Study Start Date :||June 2011|
|Estimated Primary Completion Date :||June 2013|
No Intervention: Linezolid alone
the control group is designed for linezolid alone treated MRSA VAP (standard treatment).
the intervention group was designed for combined linezolid plus imipenem for treating MRSA VAP
- MRSA eradication [ Time Frame: 7 th day ]The investigators study the efficacy of Linezolid combined with Imipenem to treat the MRSA VAP, the investigators proposed the 7th day's MRSA eradication would be better than Linezolid alone.
- MRSA eradication [ Time Frame: 14th day ]
- mortality [ Time Frame: 28th day ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01356472
|Contact: Zhi-Tao Yang, M.D.||firstname.lastname@example.org|
|Study Director:||Er-Zhen Chen, M.D. & Ph.D.||Emergency intensive care unit, Ruijin Hospital|
|Principal Investigator:||Hong-Ping Qu, M.D.||Respiratory intensive care unit, Ruijin Hospital|
|Principal Investigator:||Yu-Xing Ni, M.D. & Ph.D.||Microbiology laboratory, Ruijin Hospital|
|Study Chair:||Zhi-Tao Yang, M.D.||Emergency Department, Ruijin Hospital|